Tositumomab I-131

DB17991InvestigationalProtein Based TherapiesCD20-directed Radiotherapeutic Antibody

Tositumomab I-131: Overview.

Mechanism
Curator reviewed
First approval
United States, 2009
Also known as
131I-tositumomab · Anti-b1 antibody I-131 · Iodine (131I) tositumomab · Iodine I 131 tositumomab · Iodine I131 tositumomab

Resolves to

Compound
UNIIK1KT5M40JCCAS192391-48-3
Clinical / RWD
RxNorm234449
Targets
P11836MS4A1P31994FCGR2B

What you can answer from here — as of December 10, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
15Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Marketed productsAcross 1 country and 1 labeller
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tositumomab I-131, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In